ALGS Projected Dividend Yield

Aligos Therapeutics Inc ( NASDAQ : ALGS )

Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of non-alcoholic steatohepatitis (NASH), coronavirus (e.g., Severe Acute Respiratory Syndrome coronavirus 2 and related infections) and chronic hepatitis B. Co.'s primary area of focus is NASH, a chronic liver disease. Co.'s primary drug candidate for NASH is ALG-055009, a small molecule thyroid hormone receptor agonist. This drug candidate is being evaluated in a Phase 1 study in healthy volunteers (oral single ascending doses and subjects with hyperlipidemia (14 oral daily doses).

20 YEAR PERFORMANCE RESULTS